Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CareMax, Inc. Market Cap
From what 0 stock analysts predict, the share price for CareMax, Inc. (CMAX) might increase by 1372.85% in the next year. This is based on a 12-month average estimation for CMAX. Price targets go from $2.2 to $120. The majority of stock analysts believe CMAX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedCMAX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect CareMax, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CMAX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CMAX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| A.J. Rice UBS | Neutral | $6.4 | Maintains | Apr 1, 2024 |
| A.J. Rice UBS | Neutral | $1 | Downgrade | Nov 17, 2023 |
| Jessica Tassan Piper Sandler | Neutral | $2 | Downgrade | Nov 10, 2023 |
| Andrew Mok UBS | Buy | $6 | Maintains | Jan 6, 2023 |
| Jailendra Singh Truist Securities | Hold | $7.5 | Initiates | Sep 7, 2022 |
| Brian Tanquilut Jefferies | Buy | $15 | Initiates | Oct 20, 2021 |
Piper Sandler | Overweight | Upgrade | Sep 13, 2021 | |
Cowen & Co. | Outperform | Initiates | Sep 10, 2021 | |
Piper Sandler | Neutral | Initiates | Jul 1, 2021 |
When did it IPO
2020
Staff Count
1,450
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Carlos A. de Solo
Market Cap
$12.1M
In 2023, CMAX generated $751.1M in revenue, which was a increase of 19.01% from the previous year. This can be seen as a signal that CMAX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - MIAMI--(BUSINESS WIRE)--CareMax, Inc. (NASDAQ: CMAX; CMAXW) (“CareMax” or the “Company”), a leading technology-enabled value-based care delivery system, today announced financial results for the second quarter ended June 30, 2024. “Although our medical expense ratio continued to run higher than target levels, we were able to manage toward another quarter of sequential improvement in MER in the second quarter, and we continued to make progress against our clinical initiatives,” said Carlos de So.
Fri, 09 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - CareMax, Inc. (CMAX) came out with a quarterly loss of $10.48 per share versus the Zacks Consensus Estimate of a loss of $7.51. This compares to loss of $4.50 per share a year ago.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Student Transportation of America for Data Breach.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - OKLAHOMA CITY--(BUSINESS WIRE)-- #FMU--Federman & Sherwood Investigates Florida Memorial University (“FMU”) for Data Breach.
Thu, 09 May 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - MIAMI--(BUSINESS WIRE)--CareMax, Inc. (NASDAQ: CMAX; CMAXW) (“CareMax” or the “Company”), a leading technology-enabled value-based care delivery system, today announced financial results for the first quarter ended March 31, 2024. “During the first quarter of 2024, we believe we began to see benefits from our fourth quarter clinical efforts which became fully implemented toward the end of last year,” said Carlos de Solo, Chief Executive Officer. “While absolute levels of utilization remained el.
Sun, 07 Apr 2024
Sentiment - NEGATIVE
Source - InvestorPlace
Summary - There's an old Wall Street adage that says “the market can stay irrational longer than you can stay solvent.” We saw that play out time and again with certain beaten-down stocks.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
